The biggest item relative to Zertane is the patent portfolio covering the combination of ED and PE. Certainly PE is big, and the fact that the FDA is even entertaining a drug for what they had previously refused to consider a medical condition is huge. However, as Viagra, Cialis et. al. come off patent, big pharma needs the next big thing is this field. To be able to go after the PE market in the US is a big incentive for them, but to be able to combine it with ED, thus extending the branded life of their products is enormous.
Yes... AMPE will most likely not internally develop and market Zertane. The opportunity and benefit to big pharma is too great.
I don't expect too much up front, but there should be some huge milestone payments down the road and/or a significant prospect of an ongoing revenue stream.
Zertane appears to be somewhat of outlier in AMPE's portfolio. Expect it to be gone within a short period time, but providing some funding and revenue streams to support their other (even greater) revenue opportunities.
"the fact that the FDA is even entertaining a drug for what they had previously refused to consider a medical condition is huge. "
How? The FDA is required by law to consider all applications.
The bigger tell is that AMPE went from writing, about Zertane, (in December investor presentation on website) "two concurrent Phase III pivotal trials set to begin enrollment in 1Q13" to now apparently changing its mind.